Phong Tran is an upcoming CEO for both Bound Therapeutics LLC, leads a groundbreaking team in generative AI/ML-optimized peptide-antimiRNA21-NP targeting deadly cancer mutations, and siRnaMed Therapeutics Corp, where his team focus lies in PCL-pre-siRNA-iRhom1 nanoparticles targeting drug-resistant cancers. With a comprehesive 32 years of biopharma industry experience, Phong has traversed roles from a diligent bench scientist to recent positions such as business bevelopment and subject-matter-expert directors. His expertise spans RNA, Peptide and GPCR therapeutics, and he has contributed significantly to both start-ups and established global medtech, pharmaceutical and CRO companies. He also serves as a biopharma expert consultant to Techspert, a Cambridge UK-based consulting firm and on the boards of a handful companies. His expertise extends to numerous biopharmaceutical and medtech companies across the US, EU, and SE Asia. Phong’s contributions bridge geographical boundaries, fostering innovation and collaboration in a technology-driven ecosystem of healthcare and life sciences.